infinito
bayer ag - benzocainum,ethyli nicotinas,phenylbutazonum,hexyli nicotinas - emulsiovoide - ei-steroidiset paikalliset tulehduslääkkeet, yhdistelmävalmisteet
ilumetri
almirall s.a - tildrakizumab - psoriasis - immunosuppressantit, interleukiinin estäjät, - ilumetri on tarkoitettu hoitoon aikuisilla, joilla on kohtalainen tai vaikea läiskäpsoriaasi, jotka ovat ehdokkaita systeeminen hoito.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
epysqli
samsung bioepis nl b.v. - ekulitsumabi - hemoglobinuria, paroxysmal - immunosuppressantit - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.
bekemv
amgen technology (ireland) uc - ekulitsumabi - hemoglobinuria, paroxysmal - immunosuppressantit - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). todisteita kliininen hyöty on osoitettu potilailla, joilla on hemolyysi kanssa kliinisiä oireita(s) osoittaa korkea taudin aktiivisuus, riippumatta siitä, verensiirtoon historia (ks. kohta 5.
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - muut sydänvalmisteet - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
entresto
novartis europharm limited - sacubitril, valsartaanin - sydämen vajaatoiminta - angiotensiini ii-reseptorin salpaajat, muut yhdistelmät, agentit reniini-angiotensiini-järjestelmä - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.
kisplyx
eisai gmbh - lenvatinib-mesilaatti - karsinooma, munuaissolut - antineoplastiset aineet - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
neparvis
novartis europharm limited - sacubitril, valsartaanin - sydämen vajaatoiminta - reniini-angiotensiinijärjestelmään vaikuttavat aineet - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
lisipril comp 20 mg / 12.5 mg tabletti
orion corporation - lisinoprilum dihydricum,hydrochlorothiazidum - tabletti - 20 mg / 12.5 mg - lisinopriili ja diureetit